Lulek, Janina

Link to this page

Authority KeyName Variants
b2a6398d-f743-4ed9-9734-441d96047adc
  • Lulek, Janina (1)
Projects

Author's Bibliography

The influence of directly compressible fillers/diluents on selected compact properties and drug dissolution: a case study of rivaroxaban

Vasiljević, Ivana; Pasik, Paulina; Turković, Erna; Ivković, Branka; Hejduk, Arkadiusz; Lulek, Janina; Parojčić, Jelena

(Macedonian Pharmaceutical Association, 2023)

TY  - CONF
AU  - Vasiljević, Ivana
AU  - Pasik, Paulina
AU  - Turković, Erna
AU  - Ivković, Branka
AU  - Hejduk, Arkadiusz
AU  - Lulek, Janina
AU  - Parojčić, Jelena
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5072
AB  - Direct compression represents a favorable tablet
manufacturing method. However, obtaining satisfactory
mechanical properties of the compacts and drug dissolution
remains a challenge in formulation development,
particularly in the case of challenging model drugs.
Rivaroxaban is classified as a class II model drug
according to the Biopharmaceutical Classification System
and exhibits prominent cohesiveness and low aqueous
solubility (Choi et al., 2022). The aim of this work was to
evaluate the influence of different directly compressible
fillers/diluents on selected compact properties (namely,
tensile strength, friability, and disintegration) and the
dissolution of rivaroxaban from the prepared compacts.
PB  - Macedonian Pharmaceutical Association
PB  - Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy
C3  - Macedonian Pharmaceutical Bulletin
T1  - The influence of directly compressible fillers/diluents on selected compact properties and drug dissolution: a case study of rivaroxaban
VL  - 69
IS  - Suppl 1
SP  - 289
EP  - 290
DO  - 10.33320/maced.pharm.bull.2023.69.03.140
ER  - 
@conference{
author = "Vasiljević, Ivana and Pasik, Paulina and Turković, Erna and Ivković, Branka and Hejduk, Arkadiusz and Lulek, Janina and Parojčić, Jelena",
year = "2023",
abstract = "Direct compression represents a favorable tablet
manufacturing method. However, obtaining satisfactory
mechanical properties of the compacts and drug dissolution
remains a challenge in formulation development,
particularly in the case of challenging model drugs.
Rivaroxaban is classified as a class II model drug
according to the Biopharmaceutical Classification System
and exhibits prominent cohesiveness and low aqueous
solubility (Choi et al., 2022). The aim of this work was to
evaluate the influence of different directly compressible
fillers/diluents on selected compact properties (namely,
tensile strength, friability, and disintegration) and the
dissolution of rivaroxaban from the prepared compacts.",
publisher = "Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy",
journal = "Macedonian Pharmaceutical Bulletin",
title = "The influence of directly compressible fillers/diluents on selected compact properties and drug dissolution: a case study of rivaroxaban",
volume = "69",
number = "Suppl 1",
pages = "289-290",
doi = "10.33320/maced.pharm.bull.2023.69.03.140"
}
Vasiljević, I., Pasik, P., Turković, E., Ivković, B., Hejduk, A., Lulek, J.,& Parojčić, J.. (2023). The influence of directly compressible fillers/diluents on selected compact properties and drug dissolution: a case study of rivaroxaban. in Macedonian Pharmaceutical Bulletin
Macedonian Pharmaceutical Association., 69(Suppl 1), 289-290.
https://doi.org/10.33320/maced.pharm.bull.2023.69.03.140
Vasiljević I, Pasik P, Turković E, Ivković B, Hejduk A, Lulek J, Parojčić J. The influence of directly compressible fillers/diluents on selected compact properties and drug dissolution: a case study of rivaroxaban. in Macedonian Pharmaceutical Bulletin. 2023;69(Suppl 1):289-290.
doi:10.33320/maced.pharm.bull.2023.69.03.140 .
Vasiljević, Ivana, Pasik, Paulina, Turković, Erna, Ivković, Branka, Hejduk, Arkadiusz, Lulek, Janina, Parojčić, Jelena, "The influence of directly compressible fillers/diluents on selected compact properties and drug dissolution: a case study of rivaroxaban" in Macedonian Pharmaceutical Bulletin, 69, no. Suppl 1 (2023):289-290,
https://doi.org/10.33320/maced.pharm.bull.2023.69.03.140 . .